Skip to content

AETHLON MEDICAL, INC.: 10-Q filed 2016-11-10

What AETHLON MEDICAL, INC. reported in its quarterly report filed 2016-11-10 (fiscal Q2 2017): 26 published measures, 67 facts as tagged in accession 0001683168-16-000543.

This filing

Form
10-Q (quarterly report)
Filed
2016-11-10
Fiscal period
fiscal Q2 2017
Accession
0001683168-16-000543 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AETHLON MEDICAL, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-09-30950,835USD
At 2016-03-312,529,116USD
At 2015-09-304,705,475USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-09-301,084,221USD
At 2016-03-311,026,750USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-09-30-67,632USD
At 2016-03-311,552,720USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-2,255,586USD92
2016-04-01 to 2016-09-30-4,384,602USD183
2015-07-01 to 2015-09-30-1,224,606USD92
2015-04-01 to 2015-09-30-2,407,642USD183

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-04-01 to 2016-09-302,961USD183
2015-04-01 to 2015-09-300USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-09-30-90,886,645USD
At 2016-03-31-86,502,043USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-09-3022,969USD
At 2016-03-3136,038USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-07-01 to 2016-09-301,523,280USD92
2016-04-01 to 2016-09-301,573,991USD183
2015-07-01 to 2015-09-3050,711USD92
2015-04-01 to 2015-09-30101,421USD183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-2,226,678USD92
2016-04-01 to 2016-09-30-3,358,529USD183
2015-07-01 to 2015-09-30-1,124,361USD92
2015-04-01 to 2015-09-30-2,214,332USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-09-30816,540USD
At 2016-03-312,376,502USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-04-01 to 2016-09-3077,433USD183
2015-04-01 to 2015-09-30252,107USD183

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-09-301,084,221USD
At 2016-03-31526,611USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2016-09-30384,728USD
At 2016-03-31244,804USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2016-09-3089,579USD
At 2016-03-3194,161USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2016-09-30193,719USD
At 2016-03-31199,471USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-07-01 to 2016-09-302,614,116USD92
2016-04-01 to 2016-09-303,750,602USD183
2015-07-01 to 2015-09-301,312,727USD92
2015-04-01 to 2015-09-302,595,206USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-07-01 to 2016-09-30280,860USD92
2016-04-01 to 2016-09-30377,843USD183
2015-07-01 to 2015-09-30207,676USD92
2015-04-01 to 2015-09-30424,267USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-09-307,711,811shares
At 2016-03-317,622,393shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-09-3090,811,302USD
At 2016-03-3188,047,142USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2016-09-30-133,386USD
At 2016-03-311,502,366USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2016-09-3066,469USD
At 2016-03-3153,294USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-2,263,254USD92
2016-04-01 to 2016-09-30-4,400,002USD183
2015-07-01 to 2015-09-30-1,251,606USD92
2015-04-01 to 2015-09-30-2,468,265USD183

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-07-01 to 2016-09-30290,131USD92
2016-04-01 to 2016-09-30513,681USD183
2015-07-01 to 2015-09-30325,670USD92
2015-04-01 to 2015-09-30611,695USD183

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2016-04-01 to 2016-09-3020,612USD183
2015-04-01 to 2015-09-3018,676USD183

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-04-01 to 2016-09-30266,612USD183
2015-04-01 to 2015-09-305,591,988USD183

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-04-01 to 2016-09-30-5,752USD183
2015-04-01 to 2015-09-30-6,533USD183

Inspect the source

Entity
AETHLON MEDICAL, INC. / CIK 0000882291
Captured
SEC response SHA-256
8edef8396a760acc426ab35ab8234b202fee7f6b25b28f476090f7f70ae3999f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000882291.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))